Bonnie L. Bassler, a director at Regeneron Pharmaceuticals ($REGN), sold shares on the open market twice in the last year for a total of $1.77 million. Her most recent sale occurred on January 7, 2026. These sales rank 3,734th among 11,678 individual insiders, below the average of $8.6 million per seller and 6.4 transactions. Bassler made no open market purchases during this period.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| March 31, 2026 | Royalty Pharma plc | $RPRX | Bassler Bonnie L | Director | A | Class A Ordinary Shares | 815 | $45.98 | 73,947.0000 | 564,455,000 | 1.11% | 0.00% |
| Jan. 7, 2026 | REGENERON PHARMACEUTICALS, INC. | $REGN | Bassler Bonnie L | Director | M | Non-Qualified Stock Option (right to buy) | 1500 | $0.00 | 2,861.0000 | 137,600,000 | 34.40% | 0.00% |
| Jan. 7, 2026 | REGENERON PHARMACEUTICALS, INC. | $REGN | Bassler Bonnie L | Director | S | Common Stock | 1500 | $800.00 | 1,703.0000 | 137,600,000 | 46.83% | 0.00% |
| Jan. 7, 2026 | REGENERON PHARMACEUTICALS, INC. | $REGN | Bassler Bonnie L | Director | M | Common Stock | 1500 | $374.12 | 3,203.0000 | 137,600,000 | 88.08% | 0.00% |
| Jan. 7, 2026 | Cidara Therapeutics, Inc. | $CDTX | Bassler Bonnie L | Director | D | Stock Option (right to buy) | 2125 | $0.00 | 0.0000 | 31,439,371 | 100.00% | 0.01% |
| Jan. 7, 2026 | Cidara Therapeutics, Inc. | $CDTX | Bassler Bonnie L | Director | D | Common Stock | 15 | $221.50 | 0.0000 | 31,439,371 | 100.00% | 0.00% |
| Jan. 7, 2026 | Cidara Therapeutics, Inc. | $CDTX | Bassler Bonnie L | Director | D | Stock Option (right to buy) | 1750 | $0.00 | 0.0000 | 31,439,371 | 100.00% | 0.01% |
| Jan. 7, 2026 | Cidara Therapeutics, Inc. | $CDTX | Bassler Bonnie L | Director | D | Stock Option (right to buy) | 11100 | $0.00 | 0.0000 | 31,439,371 | 100.00% | 0.04% |
| Jan. 7, 2026 | Cidara Therapeutics, Inc. | $CDTX | Bassler Bonnie L | Director | D | Stock Option (right to buy) | 16000 | $0.00 | 0.0000 | 31,439,371 | 100.00% | 0.05% |
| Jan. 7, 2026 | Cidara Therapeutics, Inc. | $CDTX | Bassler Bonnie L | Director | D | Stock Option (right to buy) | 2125 | $0.00 | 0.0000 | 31,439,371 | 100.00% | 0.01% |
| Jan. 7, 2026 | Cidara Therapeutics, Inc. | $CDTX | Bassler Bonnie L | Director | D | Stock Option (right to buy) | 875 | $0.00 | 0.0000 | 31,439,371 | 100.00% | 0.00% |
| Jan. 7, 2026 | Cidara Therapeutics, Inc. | $CDTX | Bassler Bonnie L | Director | D | Stock Option (right to buy) | 1400 | $0.00 | 0.0000 | 31,439,371 | 100.00% | 0.00% |
| Jan. 2, 2026 | REGENERON PHARMACEUTICALS, INC. | $REGN | Bassler Bonnie L | Director | A | Non-Qualified Stock Option (right to buy) | 1962 | $0.00 | 1,962.0000 | 137,600,000 | 9999.99% | 0.00% |
| Jan. 2, 2026 | REGENERON PHARMACEUTICALS, INC. | $REGN | Bassler Bonnie L | Director | A | Common Stock | 155 | $0.00 | 1,703.0000 | 137,600,000 | 10.01% | 0.00% |
| Dec. 31, 2025 | Royalty Pharma plc | $RPRX | Bassler Bonnie L | Director | A | Class A Ordinary Shares | 967 | $38.74 | 73,132.0000 | 566,754,000 | 1.34% | 0.00% |
| Nov. 20, 2025 | REGENERON PHARMACEUTICALS, INC. | $REGN | Bassler Bonnie L | Director | M | Common Stock | 760 | $371.40 | 2,308.0000 | 136,200,000 | 49.10% | 0.00% |
| Nov. 20, 2025 | REGENERON PHARMACEUTICALS, INC. | $REGN | Bassler Bonnie L | Director | M | Non-Qualified Stock Option (right to buy) | 760 | $0.00 | 756.0000 | 136,200,000 | 50.13% | 0.00% |
| Nov. 20, 2025 | REGENERON PHARMACEUTICALS, INC. | $REGN | Bassler Bonnie L | Director | S | Common Stock | 760 | $750.00 | 1,548.0000 | 136,200,000 | 32.93% | 0.00% |
| Sept. 30, 2025 | Royalty Pharma plc | $RPRX | Bassler Bonnie L | Director | A | Class A Ordinary Shares | 1047 | $35.79 | 72,165.0000 | 594,108,000 | 1.47% | 0.00% |
| June 30, 2025 | Royalty Pharma plc | $RPRX | Bassler Bonnie L | Director | A | Class A Ordinary Shares | 1064 | $35.24 | 71,118.0000 | 594,108,000 | 1.52% | 0.00% |
| June 18, 2025 | Cidara Therapeutics, Inc. | $CDTX | Bassler Bonnie L | Director | A | Stock Option (right to buy) | 11100 | $0.00 | 11,100.0000 | 10,953,490 | 9999.99% | 0.10% |
| May 13, 2025 | Royalty Pharma plc | $RPRX | Bassler Bonnie L | Director | A | Class A Ordinary Shares | 7614 | $0.00 | 70,054.0000 | 594,108,000 | 12.19% | 0.00% |
| March 31, 2025 | Royalty Pharma plc | $RPRX | Bassler Bonnie L | Director | A | Class A Ordinary Shares | 1141 | $32.87 | 62,440.0000 | 594,108,000 | 1.86% | 0.00% |
| Jan. 2, 2025 | REGENERON PHARMACEUTICALS, INC. | $REGN | Bassler Bonnie L | Director | A | Non-Qualified Stock Option (right to buy) | 1958 | $0.00 | 1,958.0000 | 136,000,000 | 9999.99% | 0.00% |
| Jan. 2, 2025 | REGENERON PHARMACEUTICALS, INC. | $REGN | Bassler Bonnie L | Director | A | Common Stock | 166 | $0.00 | 1,548.0000 | 136,000,000 | 12.01% | 0.00% |
| Dec. 31, 2024 | Royalty Pharma plc | $RPRX | Bassler Bonnie L | Director | A | Class A Ordinary Shares | 1503 | $24.94 | 61,299.0000 | 595,683,000 | 2.51% | 0.00% |
| Dec. 17, 2024 | Cidara Therapeutics, Inc. | $CDTX | Bassler Bonnie L | Director | A | Stock Option (right to buy) | 16000 | $0.00 | 16,000.0000 | 0 | 9999.99% | 0.00% |
| Sept. 30, 2024 | Royalty Pharma plc | $RPRX | Bassler Bonnie L | Director | A | Class A Ordinary Shares | 1342 | $27.92 | 59,796.0000 | 602,900,000 | 2.30% | 0.00% |
| Aug. 15, 2024 | REGENERON PHARMACEUTICALS, INC. | $REGN | Bassler Bonnie L | Director | M | Common Stock | 756 | $371.40 | 2,138.0000 | 134,800,000 | 54.70% | 0.00% |
| Aug. 15, 2024 | REGENERON PHARMACEUTICALS, INC. | $REGN | Bassler Bonnie L | Director | S | Common Stock | 756 | $1170.00 | 1,382.0000 | 134,800,000 | 35.36% | 0.00% |
| Aug. 15, 2024 | REGENERON PHARMACEUTICALS, INC. | $REGN | Bassler Bonnie L | Director | M | Non-Qualified Stock Option (right to buy) | 756 | $0.00 | 1,516.0000 | 134,800,000 | 33.27% | 0.00% |
| Aug. 2, 2024 | REGENERON PHARMACEUTICALS, INC. | $REGN | Bassler Bonnie L | Director | M | Non-Qualified Stock Option (right to buy) | 756 | $0.00 | 2,272.0000 | 134,800,000 | 24.97% | 0.00% |
| Aug. 2, 2024 | REGENERON PHARMACEUTICALS, INC. | $REGN | Bassler Bonnie L | Director | S | Common Stock | 756 | $1115.00 | 1,382.0000 | 134,800,000 | 35.36% | 0.00% |
| Aug. 2, 2024 | REGENERON PHARMACEUTICALS, INC. | $REGN | Bassler Bonnie L | Director | M | Common Stock | 756 | $371.40 | 2,138.0000 | 134,800,000 | 54.70% | 0.00% |
| July 18, 2024 | Cidara Therapeutics, Inc. | $CDTX | Bassler Bonnie L | Director | A | Stock Option (right to buy) | 2125 | $0.00 | 2,125.0000 | 0 | 9999.99% | 0.00% |
| June 28, 2024 | Royalty Pharma plc | $RPRX | Bassler Bonnie L | Director | A | Class A Ordinary Shares | 1399 | $26.80 | 58,454.0000 | 602,900,000 | 2.45% | 0.00% |
| June 24, 2024 | REGENERON PHARMACEUTICALS, INC. | $REGN | Bassler Bonnie L | Director | S | Common Stock | 756 | $1062.00 | 1,382.0000 | 134,199,999 | 35.36% | 0.00% |
| June 24, 2024 | REGENERON PHARMACEUTICALS, INC. | $REGN | Bassler Bonnie L | Director | M | Non-Qualified Stock Option (right to buy) | 756 | $0.00 | 3,028.0000 | 134,199,999 | 19.98% | 0.00% |
| June 24, 2024 | REGENERON PHARMACEUTICALS, INC. | $REGN | Bassler Bonnie L | Director | M | Common Stock | 756 | $371.40 | 2,138.0000 | 134,199,999 | 54.70% | 0.00% |
| June 7, 2024 | Royalty Pharma plc | $RPRX | Bassler Bonnie L | Director | A | Class A Ordinary Shares | 9293 | $0.00 | 57,055.0000 | 602,900,000 | 19.46% | 0.00% |
| June 5, 2024 | REGENERON PHARMACEUTICALS, INC. | $REGN | Bassler Bonnie L | Director | S | Common Stock | 827 | $1011.00 | 1,382.0000 | 134,199,999 | 37.44% | 0.00% |
| June 5, 2024 | REGENERON PHARMACEUTICALS, INC. | $REGN | Bassler Bonnie L | Director | M | Common Stock | 827 | $380.95 | 2,209.0000 | 134,199,999 | 59.84% | 0.00% |
| June 5, 2024 | REGENERON PHARMACEUTICALS, INC. | $REGN | Bassler Bonnie L | Director | M | Non-Qualified Stock Option (right to buy) | 827 | $0.00 | 0.0000 | 134,199,999 | 100.00% | 0.00% |
| March 28, 2024 | Royalty Pharma plc | $RPRX | Bassler Bonnie L | Director | A | Class A Ordinary Shares | 1240 | $30.23 | 47,762.0000 | 602,900,000 | 2.67% | 0.00% |
| Feb. 26, 2024 | REGENERON PHARMACEUTICALS, INC. | $REGN | Bassler Bonnie L | Director | M | Common Stock | 854 | $391.92 | 2,236.0000 | 133,100,000 | 61.79% | 0.00% |
| Feb. 26, 2024 | REGENERON PHARMACEUTICALS, INC. | $REGN | Bassler Bonnie L | Director | S | Common Stock | 854 | $979.25 | 1,382.0000 | 133,100,000 | 38.19% | 0.00% |
| Feb. 26, 2024 | REGENERON PHARMACEUTICALS, INC. | $REGN | Bassler Bonnie L | Director | M | Non-Qualified Stock Option (right to buy) | 854 | $0.00 | 0.0000 | 133,100,000 | 100.00% | 0.00% |
| Jan. 30, 2024 | REGENERON PHARMACEUTICALS, INC. | $REGN | Bassler Bonnie L | Director | M | Common Stock | 827 | $380.95 | 2,209.0000 | 133,100,000 | 59.84% | 0.00% |
| Jan. 30, 2024 | REGENERON PHARMACEUTICALS, INC. | $REGN | Bassler Bonnie L | Director | S | Common Stock | 827 | $959.00 | 1,382.0000 | 133,100,000 | 37.44% | 0.00% |
| Jan. 30, 2024 | REGENERON PHARMACEUTICALS, INC. | $REGN | Bassler Bonnie L | Director | M | Non-Qualified Stock Option (right to buy) | 827 | $0.00 | 827.0000 | 133,100,000 | 50.00% | 0.00% |
| Jan. 2, 2024 | REGENERON PHARMACEUTICALS, INC. | $REGN | Bassler Bonnie L | Director | A | Common Stock | 135 | $0.00 | 1,382.0000 | 133,100,000 | 10.83% | 0.00% |
| Jan. 3, 2024 | REGENERON PHARMACEUTICALS, INC. | $REGN | Bassler Bonnie L | Director | M | Common Stock | 826 | $380.95 | 2,208.0000 | 133,100,000 | 59.77% | 0.00% |
| Jan. 3, 2024 | REGENERON PHARMACEUTICALS, INC. | $REGN | Bassler Bonnie L | Director | S | Common Stock | 826 | $914.00 | 1,382.0000 | 133,100,000 | 37.41% | 0.00% |
| Jan. 3, 2024 | REGENERON PHARMACEUTICALS, INC. | $REGN | Bassler Bonnie L | Director | M | Non-Qualified Stock Option (right to buy) | 826 | $0.00 | 1,654.0000 | 133,100,000 | 33.31% | 0.00% |
| Jan. 2, 2024 | REGENERON PHARMACEUTICALS, INC. | $REGN | Bassler Bonnie L | Director | A | Non-Qualified Stock Option (right to buy) | 1607 | $0.00 | 1,607.0000 | 133,100,000 | 9999.99% | 0.00% |
| Dec. 29, 2023 | Royalty Pharma plc | $RPRX | Bassler Bonnie L | Director | A | Class A Ordinary Shares | 1353 | $27.71 | 46,522.0000 | 437,972,000 | 3.00% | 0.00% |
| Dec. 13, 2023 | REGENERON PHARMACEUTICALS, INC. | $REGN | Bassler Bonnie L | Director | S | Common Stock | 610 | $870.00 | 1,247.0000 | 130,400,000 | 32.85% | 0.00% |
| Dec. 13, 2023 | REGENERON PHARMACEUTICALS, INC. | $REGN | Bassler Bonnie L | Director | M | Common Stock | 610 | $376.69 | 1,857.0000 | 130,400,000 | 48.92% | 0.00% |
| Dec. 13, 2023 | REGENERON PHARMACEUTICALS, INC. | $REGN | Bassler Bonnie L | Director | M | Non-Qualified Stock Option (right to buy) | 610 | $0.00 | 0.0000 | 130,400,000 | 100.00% | 0.00% |
| Sept. 29, 2023 | Royalty Pharma plc | $RPRX | Bassler Bonnie L | Director | A | Class A Ordinary Shares | 1384 | $27.08 | 45,169.0000 | 437,972,000 | 3.16% | 0.00% |
| Aug. 21, 2023 | REGENERON PHARMACEUTICALS, INC. | $REGN | Bassler Bonnie L | Director | S | Common Stock | 853 | $829.00 | 1,247.0000 | 130,400,000 | 40.62% | 0.00% |
| Aug. 21, 2023 | REGENERON PHARMACEUTICALS, INC. | $REGN | Bassler Bonnie L | Director | M | Common Stock | 853 | $391.92 | 2,100.0000 | 130,400,000 | 68.40% | 0.00% |
| Aug. 21, 2023 | REGENERON PHARMACEUTICALS, INC. | $REGN | Bassler Bonnie L | Director | M | Non-Qualified Stock Option (right to buy) | 853 | $0.00 | 854.0000 | 130,400,000 | 49.97% | 0.00% |
| Aug. 10, 2023 | REGENERON PHARMACEUTICALS, INC. | $REGN | Bassler Bonnie L | Director | M | Non-Qualified Stock Option (right to buy) | 853 | $0.00 | 1,707.0000 | 130,400,000 | 33.32% | 0.00% |
| Aug. 10, 2023 | REGENERON PHARMACEUTICALS, INC. | $REGN | Bassler Bonnie L | Director | S | Common Stock | 853 | $789.00 | 1,247.0000 | 130,400,000 | 40.62% | 0.00% |
| Aug. 10, 2023 | REGENERON PHARMACEUTICALS, INC. | $REGN | Bassler Bonnie L | Director | M | Common Stock | 853 | $391.92 | 2,100.0000 | 130,400,000 | 68.40% | 0.00% |
| June 30, 2023 | Royalty Pharma plc | $RPRX | Bassler Bonnie L | Director | A | Class A Ordinary Shares | 1208 | $31.03 | 43,785.0000 | 437,972,000 | 2.84% | 0.00% |
| June 23, 2023 | Royalty Pharma plc | $RPRX | Bassler Bonnie L | Director | A | Class A Ordinary Shares | 7747 | $0.00 | 42,577.0000 | 437,972,000 | 22.24% | 0.00% |
| March 31, 2023 | Royalty Pharma plc | $RPRX | Bassler Bonnie L | Director | A | Class A Ordinary Shares | 1049 | $35.73 | 34,830.0000 | 437,972,000 | 3.11% | 0.00% |
| March 24, 2023 | REGENERON PHARMACEUTICALS, INC. | $REGN | Bassler Bonnie L | Director | S | Common Stock | 1240 | $818.00 | 1,247.0000 | 130,400,000 | 49.86% | 0.00% |
| March 24, 2023 | REGENERON PHARMACEUTICALS, INC. | $REGN | Bassler Bonnie L | Director | M | Common Stock | 1240 | $380.95 | 2,487.0000 | 130,400,000 | 99.44% | 0.00% |
| March 24, 2023 | REGENERON PHARMACEUTICALS, INC. | $REGN | Bassler Bonnie L | Director | M | Non-Qualified Stock Option (right to buy) | 1240 | $0.00 | 2,480.0000 | 130,400,000 | 33.33% | 0.00% |
| Feb. 3, 2023 | REGENERON PHARMACEUTICALS, INC. | $REGN | Bassler Bonnie L | Director | M | Common Stock | 1021 | $380.95 | 2,268.0000 | 130,400,000 | 81.88% | 0.00% |
| Feb. 3, 2023 | REGENERON PHARMACEUTICALS, INC. | $REGN | Bassler Bonnie L | Director | M | Non-Qualified Stock Option (right to buy) | 1021 | $0.00 | 3,720.0000 | 130,400,000 | 21.54% | 0.00% |
| Feb. 3, 2023 | REGENERON PHARMACEUTICALS, INC. | $REGN | Bassler Bonnie L | Director | S | Common Stock | 1021 | $779.00 | 1,247.0000 | 130,400,000 | 45.02% | 0.00% |
| Jan. 3, 2023 | REGENERON PHARMACEUTICALS, INC. | $REGN | Bassler Bonnie L | Director | A | Common Stock | 165 | $0.00 | 1,247.0000 | 130,400,000 | 15.25% | 0.00% |
| Jan. 3, 2023 | REGENERON PHARMACEUTICALS, INC. | $REGN | Bassler Bonnie L | Director | A | Non-Qualified Stock Option (right to buy) | 1929 | $0.00 | 1,929.0000 | 130,400,000 | 9999.99% | 0.00% |
| Dec. 30, 2022 | Royalty Pharma plc | $RPRX | Bassler Bonnie L | Director | A | Class A Ordinary Shares | 943 | $39.76 | 33,781.0000 | 0 | 2.87% | 0.00% |